Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Lactobacillus rhamnosus GG

LGG · ATCC 53103 · The Reference Probiotic Strain

Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.

The current rating of 4 reflects the marketed halo of the world's most-studied probiotic strain rather than what the trials support once they are read carefully. The evidence is genuinely strain-specific and use-specific. For prevention of antibiotic-associated diarrhea, Szajewska and Kolodziej (Aliment Pharmacol Ther, 2015) pooled 12 RCTs (1,499 participants) and found LGG cut AAD risk from 22.4% to 12.3% (RR 0.49, 95% CI 0.29-0.83), with the effect statistically significant in children (RR 0.48) and in the H. pylori eradication subgroup (RR 0.26) but not significant overall in adults; GRADE was rated moderate to low. That is solid mid-tier evidence, so the AAD use earns a 3. The two most rigorous trials for acute pediatric gastroenteritis, Schnadower et al. (NEJM 2018, 971 children) and the companion Freedman et al. combination-probiotic trial (NEJM 2018), both found no benefit over placebo for the primary outcome, prompting the AGA (2020) to suggest against probiotics for acute gastroenteritis in North American children. For primary eczema prevention, Szajewska and Horvath (2018) pooled 5 RCTs (889 infants) and found no reduction in eczema risk (RR 0.90, 95% CI 0.67-1.21), reversing the optimism from the original Kalliomaki trials. Averaging one moderate-evidence win against several well-powered negative results, a rating of 3 (mixed to moderate) is the honest grade for LGG as a whole.

FDA
Legal supplement (DSHEA)
WADA
Not prohibited

Reference only. Not medical advice.

What can go wrong

Very safe for healthy users; genuine bacteremia and sepsis risk in the severely immunocompromised, critically ill, or catheterized, who should avoid probiotics outside specific clinical protocols.

Lactobacillus rhamnosus GG (now reclassified Lacticaseibacillus rhamnosus GG, ATCC 53103) is the single most-studied probiotic strain, isolated in 1983 by Sherwood Gorbach and Barry Goldin, whose surnames give the 'GG.' Its best-supported use is preventing antibiotic-associated diarrhea, where a 2015 meta-analysis of 12 RCTs showed a real reduction, strongest in children and during H. pylori therapy. Two large 2018 NEJM trials found no benefit for acute childhood gastroenteritis, and a 2018 meta-analysis found no benefit for preventing eczema, so several of its popular reputations have not held up. The strain is a useful case study in why the exact strain name, not just the species, is what carries the evidence.

The reference probiotic, and proof that the strain name actually matters.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Preventing antibiotic-associated diarrhea (best supported, strongest in children and during H. pylori eradication)
  • Reducing Clostridioides difficile risk during antibiotics (as part of guideline-endorsed strain options)
  • Shortening acute infectious diarrhea (modest, dose- and timing-dependent; contested after 2018)
  • Acute pediatric gastroenteritis (no benefit in the two large 2018 NEJM trials)
  • Primary prevention of eczema/atopic dermatitis (not supported by 2018 meta-analysis)
  • General daily gut-maintenance routine (traditional use, weak direct evidence)

How it is supposed to work

Lactobacillus rhamnosus GG (LGG, ATCC 53103) is a single specific bacterial strain, not a species, a strain. Its mechanisms include competitive exclusion of pathogenic bacteria, modulation of intestinal epithelial barrier function (tight junction stabilization), production of antimicrobial peptides, modulation of the gut-associated immune system (cytokine signaling, regulatory T-cell function), and short-chain fatty acid production. Strain specificity is a real and consequential principle: different L. rhamnosus strains produce different clinical effects, and generic "Lactobacillus rhamnosus" on a label does not guarantee LGG bioactive properties.

How it is taken

LGG is typically dosed at 10 billion CFU daily in adult Culturelle Daily Probiotic (or equivalent LGG-specific products), the foundational adult dose framework established through substantial clinical research. Pediatric dosing is typically 5 billion CFU daily through Culturelle Kids or equivalent pediatric formulations. Take consistently, probiotic effects work through sustained microbiome influence rather than acute pharmacological effect; missing doses occasionally is unlikely to substantially affect outcomes, but sustained daily use over weeks to months allows microbiome assessment. The substantial clinical evidence framework for LGG-specific applications includes: antibiotic-associated diarrhea prevention (start concurrent with antibiotic, continue 1-2 weeks post-antibiotic), acute infectious diarrhea (during acute episode), atopic dermatitis/eczema prevention (maternal pregnancy supplementation + infant supplementation in high-risk children), traveler's diarrhea prevention (1-2 weeks before travel + during + 1-2 weeks after), and broader gut microbiome support. Storage: room temperature acceptable for properly-formulated modern LGG products; refrigeration may extend shelf life modestly. Take with or without food; some clinical evidence supports taking with meals for optimal gastric protection. The substantial strain specificity matters, LGG (ATCC 53103) clinical evidence does not generalize to all Lactobacillus rhamnosus strains; verify specific strain identifier disclosure. The drug interaction profile is modest for most users, live probiotics generally do not produce substantial drug interactions. Antibiotic timing: separate LGG and antibiotic doses by 2-3 hours to support probiotic viability. Immunocompromised users warrant specialist coordination given theoretical bacteremia risk; documented but rare case reports across various probiotic products in severely immunocompromised contexts. Pregnancy and lactation: substantial safety record; reasonable supplementation under OB-GYN coordination. Pediatric use: substantial pediatric clinical evidence framework with Culturelle Kids pediatric formulation availability; pediatrician coordination reasonable.

Standard adult dose
10 billion CFU daily (Culturelle Daily)
Pediatric dose
5 billion CFU daily (Culturelle Kids)
Strain identifier
ATCC 53103 (verify specifically)
Antibiotic timing
Separate LGG and antibiotic doses by 2-3 hours
Antibiotic-associated diarrhea
Concurrent + 1-2 weeks post-antibiotic
Acute infectious diarrhea
During acute episode
Eczema prevention
Maternal pregnancy + infant supplementation (high-risk)
Storage
Room temperature acceptable

Which form to buy

Not all preparations of the same ingredient are the same thing, and the trials were run on particular ones.

  • Culturelle Daily Probiotic (10 billion CFU LGG)

    Rating: gold

    Substantially the most-recognized LGG-specific consumer probiotic product, Culturelle (originally i-Health, acquired by DSM, now part of DSM-Firmenich). Standardized 10 billion CFU Lactobacillus rhamnosus GG (ATCC 53103) plus inulin prebiotic. Substantial clinical evidence inheritance from LGG-specific research (Goldin & Gorbach 1985 foundational isolation, Doron 2008 review, substantial antibiotic-associated diarrhea evidence). Mass-market retail availability.

  • Culturelle Kids Probiotic (5 billion CFU LGG)

    Rating: gold

    Pediatric-formulated Culturelle product (5 billion CFU LGG, pediatric chewable or packet formulation). Substantial pediatric LGG clinical evidence (acute infectious diarrhea, antibiotic-associated diarrhea, infant colic, eczema prevention). Reasonable pediatric LGG supplementation framework.

  • Culturelle Health & Wellness (10 billion CFU LGG)

    Rating: gold

    Standard adult Culturelle formulation; substantially the most-marketed consumer LGG product globally. Mass-market retail expansion (CVS, Walgreens, Walmart, Target, Amazon, others).

  • Culturelle Digestive Daily (LGG + Inulin)

    Rating: gold

    LGG plus inulin prebiotic combination, synbiotic positioning combining probiotic LGG with prebiotic substrate. Reasonable comprehensive gut microbiome support.

  • Visbiome (Multi-Strain Including LGG-Related Strains)

    Rating: gold

    Pharmaceutical-grade multi-strain probiotic (450 billion CFU per packet across 8 strains including Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus acidophilus, Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis). Substantial pharmaceutical-grade ulcerative colitis and pouchitis clinical evidence. Not LGG-specific but related multi-strain framework with substantial Lactobacillus rhamnosus content.

  • Other LGG-Containing Multi-Strain Products

    Rating: good

    Various multi-strain probiotic products include LGG alongside other strains (some Garden of Life formulations, Nature's Way Primadophilus, various other commercial products). Verify specific LGG strain identifier (ATCC 53103) inclusion and CFU disclosure. LGG content varies substantially across multi-strain products.

  • Seed DS-01 (Includes LGG Among 24 Strains)

    Rating: gold

    Seed Health DS-01 Daily Synbiotic 24-strain formulation includes LGG alongside 23 other clinically-studied probiotic strains. Substantial multi-strain framework with substantial transparency on strain identifiers. Reasonable comprehensive multi-strain framework with LGG inclusion.

  • AG1 / Bloom / Huel Multi-Ingredient LGG Content

    Rating: caution

    Multi-ingredient greens powders typically include modest probiotic content; specific LGG inclusion varies. Substantially modest LGG dosing relative to dedicated Culturelle 10 billion CFU framework. Users seeking therapeutic LGG dosing should use dedicated products.

Who it works for, and who it does not

  • Antibiotic-associated diarrhea prevention

    Strength of evidence for this group: modest

    Substantial clinical evidence (multiple RCTs, Cochrane review) supports LGG efficacy for antibiotic-associated diarrhea prevention in adults and children. Start LGG concurrent with antibiotic course (separated 2-3 hours from antibiotic dose) and continue 1-2 weeks post-antibiotic. Reasonable preventive framework.

  • Acute infectious diarrhea (children particularly)

    Strength of evidence for this group: modest

    Substantial pediatric clinical evidence supports LGG efficacy for acute infectious diarrhea, modest reduction in diarrhea duration (typically ~1 day reduction) and severity. Substantial pediatric framework; reasonable adjunctive supplementation alongside rehydration and standard care.

  • Atopic dermatitis / eczema prevention (pediatric)

    Strength of evidence for this group: cautious

    Substantial pediatric clinical evidence for LGG maternal supplementation during pregnancy and infant supplementation for eczema prevention in high-risk children (family history). Effect sizes modest; reasonable framework for high-risk pediatric contexts under specialist coordination.

  • Functional GI disorders (IBS, functional constipation)

    Strength of evidence for this group: cautious

    Modest evidence for LGG in IBS and functional GI disorders; effect sizes modest relative to other probiotic strain frameworks (Bifidobacterium longum 35624 has more substantial IBS-specific evidence). Reasonable adjunctive supplementation; coordinate with gastroenterology for established functional GI disease.

  • Traveler's diarrhea prevention

    Strength of evidence for this group: cautious

    Modest clinical evidence for LGG in traveler's diarrhea prevention; reasonable preventive framework. Initiate 1-2 weeks before travel; continue during and 1-2 weeks after travel.

  • Vaginal microbiome support

    Strength of evidence for this group: cautious

    Some evidence for Lactobacillus strains in vaginal microbiome support; LGG specific evidence is limited (more substantial evidence for Lactobacillus crispatus, Lactobacillus jensenii in vaginal-specific applications). Reasonable adjunctive supplementation; consider dedicated vaginal-specific strain alternatives.

  • Pregnancy and lactation

    Strength of evidence for this group: modest

    Substantial maternal LGG supplementation during pregnancy and breastfeeding has substantial safety record. Some evidence supports maternal LGG supplementation for infant eczema prevention in high-risk infants. Reasonable supplementation under OB-GYN coordination.

  • Pediatric (general)

    Strength of evidence for this group: modest

    Substantial pediatric clinical evidence framework, LGG is among the most-studied probiotic strains in pediatric populations. Substantial Culturelle Kids pediatric formulation availability. Pediatrician coordination reasonable.

  • Immunocompromised users (caution)

    Strength of evidence for this group: cautious

    Live probiotic supplementation carries theoretical risk in severely immunocompromised users (active chemotherapy, severe immunodeficiency, central venous catheter users); documented but rare bacteremia case reports with LGG and other probiotic products. Specialist immunology coordination essential for immunocompromised contexts.

  • Inflammatory bowel disease (UC, Crohn's)

    Strength of evidence for this group: cautious

    Limited LGG-specific evidence for established IBD; Visbiome (multi-strain pharmaceutical-grade) has more substantial UC and pouchitis evidence. Coordinate with gastroenterology for established IBD; pharmaceutical-grade alternatives may be preferred.

  • Post-cesarean section infant microbiome support

    Strength of evidence for this group: cautious

    Limited evidence for LGG infant supplementation for post-C-section microbiome restoration; broader microbiome restoration research framework continues to evolve. Specialist pediatric coordination essential.

  • Allergic rhinitis adjunctive support

    Strength of evidence for this group: cautious

    Modest preliminary evidence for LGG in allergic rhinitis; effect sizes modest. Reasonable adjunctive supplementation; not substitute for established allergy management.

Taken with other things

Combinations people actually use. Evidence for one ingredient is not evidence for a pair.

  • Antibiotics (During Course)

    Interaction: synergy

    Substantial clinical evidence for LGG concurrent supplementation with antibiotic course for AAD prevention. Separate doses by 2-3 hours to support probiotic viability. Continue 1-2 weeks post-antibiotic for sustained microbiome restoration.

  • Multi-Strain Probiotic Products (Seed DS-01, Visbiome)

    Interaction: synergy

    Reasonable combination or alternative framework, multi-strain products including LGG provide broader strain diversity; dedicated LGG products provide therapeutic single-strain dosing. Choose based on specific clinical application.

  • Dietary Fiber and Fermented Foods

    Interaction: synergy

    Substantial complementary positioning, dietary fiber provides prebiotic substrate; fermented foods provide additional probiotic supplementation. Reasonable comprehensive microbiome support combining LGG supplementation with substantial dietary fiber and fermented food intake.

  • Inulin and Prebiotic Supplementation

    Interaction: synergy

    Inulin (included in Culturelle Daily) provides prebiotic substrate supporting LGG colonization. Reasonable synbiotic framework; substantial Culturelle Daily formulation reflects this combination.

  • Vitamin D3 Supplementation

    Interaction: synergy

    Vitamin D3 supports broader immune modulation framework complementary to LGG immune effects. Reasonable comprehensive immune support framework.

  • Zinc Supplementation

    Interaction: synergy

    Zinc supports broader immune function complementary to LGG mechanisms. Reasonable comprehensive immune support framework, particularly for acute infectious diarrhea contexts where zinc supplementation is established WHO recommendation alongside probiotic supplementation.

  • Immunosuppressants

    Interaction: caution

    Live probiotic supplementation in severely immunocompromised users carries theoretical bacteremia risk. Coordinate with immunology specialist; benefit-risk assessment essential.

  • Central Venous Catheter Users

    Interaction: avoid

    Documented case reports of probiotic-associated bacteremia in users with central venous catheters. Generally avoid live probiotic supplementation in CVC users without specialist coordination.

  • Pregnancy and Lactation

    Interaction: synergy

    Substantial safety record; some evidence supports maternal LGG supplementation for infant eczema prevention in high-risk infants. Reasonable supplementation under OB-GYN coordination.

  • Other Multi-Strain Probiotic Products (Combination)

    Interaction: caution

    Combining Culturelle (LGG) with other multi-strain probiotic products may produce substantial strain redundancy without proportional benefit. Reasonable choice between products rather than combination supplementation.

What to look for on the label

Look for: explicit strain identifier disclosure (ATCC 53103 for Lactobacillus rhamnosus GG); explicit CFU content per serving (10 billion CFU adult standard); appropriate dose for intended use; reputable manufacturer (Culturelle/DSM-Firmenich is foundational LGG brand); third-party testing disclosure; expiration date verification (probiotic viability matters); storage instructions consistent with product formulation. Avoid: products labeled "L. rhamnosus" without specific strain identifier disclosure (strain specificity matters substantially, LGG ATCC 53103 evidence does not generalize to all L. rhamnosus strains); products without CFU disclosure; expired products (viability concern); products from manufacturers without third-party testing disclosure; live probiotic use in severely immunocompromised users without specialist coordination; combination with multiple multi-strain products (strain redundancy without proportional benefit).

Safety in detail

  • Generally very safe in healthy users. The clinical-use safety record over four decades is extensive.
  • Real concern in severely immunocompromised users, Lactobacillus sepsis case reports exist in ICU populations, neutropenic patients, and central-line patients. Probiotics in these populations should be specialist-guided, not OTC self-management.
  • Theoretical concern in patients with damaged gut barriers (post-surgery, severe inflammatory bowel disease), bacterial translocation risk.
  • Mild gas, bloating, and changed stool pattern in the first days of use are common and resolve.
  • Refrigeration requirement varies by product, shelf-stable LGG products are widely available, but storage matters for viability.

What people get wrong

  • Often saidAll Lactobacillus rhamnosus products are equivalent.

    ActuallyStrain specificity is a real principle. Generic L. rhamnosus is not LGG. Look for the strain identifier on the label.

  • Often saidProbiotics are dangerous because they introduce live bacteria.

    ActuallyIn healthy users, the safety record is extensive. The real concern is in severely immunocompromised users, where probiotics should be specialist-guided, not OTC self-management.

  • Often saidHigher CFU count is always better.

    ActuallyThe 10 billion vs 50 billion CFU comparison is largely marketing. The strain identity and viability at point of use matter more than the headline count.

Who profits, and who pushes back

  • David Schnadower

    Pushes backLead author of negative pediatric gastroenteritis trial

    Our findings substantially complicated the prior positive evidence for LGG in acute pediatric gastroenteritis. The lesson is broader: each indication should be evaluated with high-quality trials in the relevant population. We cannot generalize from antibiotic-associated diarrhea to other acute conditions.

  • Sherwood Gorbach

    Promotes itTufts · LGG co-discoverer

    Original isolator (with Barry Goldin). Long-standing academic voice on probiotic science.

  • Mary Ellen Sanders

    Promotes itISAPP · International Scientific Association for Probiotics and Prebiotics

    Independent scientific voice on probiotic clinical evidence and terminology standardization.

  • DSM (Culturelle)

    Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.

    Promotes itMajor commercial product

    Current owner of the consumer Culturelle brand. Funds substantial portions of the LGG clinical-trial pipeline. Disclosed.

How we got here

LGG was isolated by Sherwood Gorbach and Barry Goldin at Tufts University School of Medicine in 1985, the "GG" honors their surnames. The strain was selected for its ability to survive gastric acid and adhere to intestinal epithelium. Valio (Finland) commercialized LGG in dairy products starting in 1990, and the strain became a foundational reference in modern probiotic clinical research. Over a thousand published studies have used this specific strain.

  1. 1985Gorbach and Goldin isolate LGG at Tufts
  2. 1990Valio commercializes LGG in dairy
  3. 1999Vanderhoof AAD pediatric trial
  4. 2001Kalliomäki atopic dermatitis prevention trial
  5. 2017Goldenberg Cochrane AAD confirms prevention effect
  6. 2018Schnadower NEJM complicates acute gastroenteritis evidence

What we do not know

  • Why the Schnadower 2018 NEJM trial did not replicate prior positive evidence for acute pediatric gastroenteritis, confounding variables include US versus international setting, severity profile, and rotavirus vaccination era.
  • Optimal strain combinations versus single-strain use for specific clinical indications.
  • Long-term implications of routine probiotic use in healthy adults, most evidence is short-duration.
  • How widely the strain-specificity principle generalizes, whether each probiotic clinical claim must be evaluated strain-by-strain rather than at the species level.

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

Look for the specific strain identifier on the label, "Lactobacillus rhamnosus GG" or "ATCC 53103", not generic "Lactobacillus rhamnosus." Culturelle is the dominant US commercial product with consistent strain identification. CFU count at end of shelf life (not at manufacture) is the relevant viability metric. Refrigeration extends viability for some formulations; shelf-stable products use protected-spore or microencapsulation approaches.

At a glance

Strain identifier
ATCC 53103
Discoverers
Gorbach and Goldin (1985)
Typical dose
1-20 billion CFU/day
Strongest indication
Antibiotic-associated diarrhea prevention
Major commercial product
Culturelle
Published studies
1000+

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Lactobacillus rhamnosus GG. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources

The studies that matter

  • Vanderhoof antibiotic-associated diarrhea1999

    Foundational pediatric trial: LGG significantly reduced AAD in children on antibiotics. Subsequent trials and meta-analyses replicate this effect.

  • Schnadower NEJM acute pediatric gastroenteritis2018

    Multi-center US trial: LGG did not improve outcomes in acute pediatric gastroenteritis. Substantially complicated the prior positive evidence base.

  • Goldenberg Cochrane AAD meta-analysis2017

    Pooled trial evidence supports probiotic effect on AAD prevention; LGG is the best-evidenced single strain.

  • Kalliomäki atopic dermatitis prevention2001

    LGG given prenatally and to infants reduced atopic dermatitis incidence in high-risk infants, finding that has been partially but not fully replicated in subsequent trials.